Twenty patients (15 males; five females) aged 11–70 years, with urinary tract infections were treated with one 250 mg tablet of ciprofloxacin every 12 h for 5–10 days. Clinical response to this treatment was the complete disappearance of symptoms in 85% of cases and the elimination of the micro-organism responsible for infection. In only three patients, who all had urinary calculus in addition to an infection, clinical failure of the therapy occurred and the causative micro-organism persisted. Tolerance to the therapy was excellent in this study, no adverse reactions connected with the treatment being reported.
Get full access to this article
View all access options for this article.
References
1.
BauernfeindAPetermüllerC: In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid. Eur J Clin Microbiol1983; 2: 111–115.
2.
CaekenbergheDLPattynS: In vitro activity of ciprofloxacin compared with those of other new fluorinated piperazinyl-substituted quinoline derivatives. Antimicrob Agents Chemother1984; 25: 518–521.
3.
ChinNXNeuHC: Ciprofloxacin, aquinolone carboxylic acid compound active against aerobic and anaerobic bacteria. Antimicrob Agents Chemother1984; 25: 319–326.
4.
EliopoulosGMGardellaAMoelleringRC: In vitro activity of ciprofloxacin, a new carboxyquinolone antimicrobial agent. Antimicrob Agents Chemother1984; 25: 331–335.
5.
FassRJ: In vitro activity of ciprofloxacin (Bay o 9867). Antimicrob Agents Chemother 1983; 24: 568–574.
6.
FelminghamDO'HareMDRobbinsMJ: Comparative in vitro studies with 4-quinolone antimicrobials. Drugs Exp Clin Res1985; 11: 317–329.
7.
GalanteDPennucciCEspositoS: Comparative in vitro activity of ciprofloxacin and five other quinolone derivatives against Gram-negative isolates. Drugs Exp Clin Res1985; 11: 331–334.
8.
Hoogkamp-KorstanjeJAA: Comparative in vitro activity of five quinolone derivatives and five other antimicrobial agents used in oral therapy. Eur J Clin Microbiol1984; 3: 333–338.
9.
RoyCFozASegusaA: Activity of ciprofloxacin (Bay o 9867) Against Pseudomonas aeruginosa and ampicillin-resistant enterobacteriaceae. Infection1983; 11: 326–328.
10.
ShrireISaundersJTraynorR: A laboratory assessment of ciprofloxacin and comparable antimicrobial agents. Eur J Clin Microbiol1984; 3: 328–332.
11.
WiseRAndrewsJMEdwardsLJV: In vitro activity of Bay o 9867, a new quinolone derivative, compared with those of other antimicrobial agents. Antimicrob Agents Chemother1983; 23: 559–564.
12.
ZeilerHJGroheK: The in vitro and in vivo activity of ciprofloxacin. Eur J Clin Microbiol1984; 3: 339–343.
13.
AldrigeKEJanneyASandersCV: Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus-aureus from various geographical locations. Antimicrob Agents Chemother1985; 28: 634–638.
14.
GombertMEAulicinoTM: Susceptibility of multiply antibiotic-resistant Pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin and novobiocin. Antimicrob Agents Chemother1984; 26: 933–934.
15.
KelleySGBertramMAYoungLS: Activity of ciprofloxacin against resistant clinical isolates. J Antimicrob Chemother1986; 17: 281–286.
16.
MoorhouseECMulvihillTEJonesL: The in vitro activity of some antimicrobial agents against Methicillin-resistantStaphylococcus aureus. J Antimicrob Chemother1985; 15: 291–295.
17.
SimberkoffMSRahalJJJR: Bactericidal activity of ciprofloxacin against amikacin and Cefotaxime-resistant gram-negative bacilli and Methicillin-resistantStaphylococci. Antimicrob Agents Chemother1986; 29: 1098–1100.
18.
SmithSMEngRH: Activity of ciprofloxacin against Methicillin-resistantStaphylococcus aureus. Antimicrob Agents Chemother1985; 27: 688–691.
19.
SmithSM: In vitro comparison of A-56619, A-56620, amifloxacin, ciprofloxacin, enoxacin, norfloxacin and ofloxacin against Methicillin-resistant Staphylococcus-aureus. Antimicrob Agents Chemother1986; 29: 325–326.
20.
SmithSMEngRHBermanE: The effect of ciprofloxacin on Methicillin-resistantStaphylococcus aureus. J Antimicrob Chemother1986; 17: 287–295.
21.
SpecialeABlandinoGPellegrinoMB: In vitro activity of ciprofloxacin against Aminoglycoside-sensitive and Aminoglycoside-resistant gram-negative rods. Chemioterapia1986; 5: 196–199.
22.
AronoffGEKennerCHSloanRS: Multiple-dose ciprofloxacin kinetics in normal subjects. Clin Pharmacol Ther1984; 36: 384–388.
23.
BallAPFoxCBallME: Pharmacokinetics of oral ciprofloxacin, 100 mg single dose, in volunteers and elderly patients. J Antimicrob Chemother1986; 17: 629–635.
24.
GonzalezMAUribeFMoisenSD: Multiple-dose pharmacokinetics and safety of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother1984; 26: 741–744.
25.
HoefflerDDalhoffAGauW: Dose and sex independent disposition of ciprofloxacin. Eur J Clin Microbiol1984; 3: 363–366.
26.
TartaglioneTARaffalovichACPoynorWJ: Pharmacokinetics and tolerance of ciprofloxacin after sequential increasing oral doses. Antimicrob Agents Chemother1986; 29: 62–66.
27.
WingenderWGraefeKHGauW: Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur J Clin Microbiol1984; 3: 355–359.
28.
BauerAWKirbyWMMSherrisJC: Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol1966; 45: 493–496.
29.
GuibertJDesireeDKonopkaC: Ciprofloxacin in the treatment of urinary tract infection due to enterobacteria. Eur J Clin Microbiol1986; 5: 247–248.
30.
PetersHJ: Comparison of intravenous ciprofloxacin and mezlocillin in treatment of complicated urinary tract infections. Eur J Clin Microbiol1986; 5: 253–255.
31.
SaavedraSRamirez-RondaCHNevarezM: Ciprofloxacin in the treatment of urinary tract infections caused by Pseudomonas aeruginosa and multiresistant bacteria. Eur J Clin Microbiol1986; 5: 255–257.
32.
Van PoppelHWeggeMDammekensH: Oral treatment of Pseudomonas-induced urinary tract infections with ciprofloxacin. Chemotherapy1986; 32: 83–87.
33.
GalanteDEspositoSBarbaD: Ciprofloxacin in the treatment of urinary and respiratory tract infections in patients with chronic liver disease. Chemioterapia1986; 5: 322–326.
